China Pharma Holdings (CPHI) Income from Continuing Operations: 2009-2025
Historic Income from Continuing Operations for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.
- China Pharma Holdings' Income from Continuing Operations rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
- According to the latest figures from Q3 2025, China Pharma Holdings' Income from Continuing Operations is -$651,482, which was down 23.30% from -$528,367 recorded in Q2 2025.
- Over the past 5 years, China Pharma Holdings' Income from Continuing Operations peaked at -$475,976 during Q1 2023, and registered a low of -$1.4 million during Q2 2024.
- Moreover, its 3-year median value for Income from Continuing Operations was -$785,572 (2025), whereas its average is -$889,146.
- In the last 5 years, China Pharma Holdings' Income from Continuing Operations tumbled by 6,418.56% in 2021 and then skyrocketed by 63.26% in 2025.
- Quarterly analysis of 5 years shows China Pharma Holdings' Income from Continuing Operations stood at -$980,719 in 2021, then fell by 28.90% to -$1.3 million in 2022, then grew by 2.53% to -$1.2 million in 2023, then rose by 0.63% to -$1.2 million in 2024, then spiked by 41.72% to -$651,482 in 2025.
- Its Income from Continuing Operations was -$651,482 in Q3 2025, compared to -$528,367 in Q2 2025 and -$785,572 in Q1 2025.